pyrazines has been researched along with Stroke in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (18.18) | 29.6817 |
| 2010's | 16 (72.73) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, B; Gao, G; Meng, S | 1 |
| Chen, J; Dong, L; Dong, Y; Fu, X; Guo, T; Liu, M; Mao, Y; Qiao, C; Yang, Y; Zhang, J; Zhang, X; Zhao, Y | 1 |
| Cao, H; Ge, L; Xu, M; Zhang, C; Zhang, J; Zhu, X | 1 |
| Alexander, JC; Candelario-Jalil, E; DeMars, KM; Febo, M; Yang, C | 1 |
| Gong, X; He, X; Sun, M; Sun, Y; Wang, BO; Wang, M; Wang, X; Wang, Z; Wei, X; Yi, F; Zhang, Y; Zhou, Z | 1 |
| Cao, J; Chen, H; Li, N; Liu, W; Liu, Y; Sun, Y; Wang, Y; Wu, L; Zhang, G; Zhang, Z | 1 |
| Andersson, C; Mogensen, UM; Scheller, NM; Torp-Pedersen, C; Vaag, A | 1 |
| Bethel, MA; Califf, RM; Green, JB; Holman, RR; Kaufman, KD; Paul, SK; Ring, A; Shapiro, DR | 1 |
| Cheung, YK | 1 |
| Chen, DY; Chen, TH; Cherng, WJ; Chou, CC; Hsieh, IC; Hung, KC; Lin, YS; Mao, CT; Su, FC; Tsai, ML; Wang, CC; Wang, SH; Wen, MS | 1 |
| Chen, C; Hao, Y; Hong, Y; Lei, H; Li, G; Tian, Y; Wang, P; Zhang, Y | 1 |
| Bednar, MM; Di Cesare, F; Loudon, PT; Mancuso, J; Woodward, P | 1 |
| Chu, IK; Law, HC; Lee, SM; Li, G; Quan, Q; Sho, E; Siu, MK; Sun, Y; Szeto, SS; Wang, Y; Yu, P; Zhang, G; Zhang, Z | 1 |
| Jiang, J; Liu, W; Sun, Y; Wang, L; Wang, Y; Xu, C; Yu, P; Zhang, Z | 1 |
| Guo, HF; Mao, JJ; Su, HL; Sun, C; Wang, J; Zhou, X | 1 |
| Chen, H; Jiang, J; Li, S; Wang, X; Wang, Y; Wu, J | 1 |
| Cheng, Y; Sun, J; Wang, H; Yang, C; Zhang, S | 1 |
| Chopp, M; Zhang, L; Zhang, ZG | 1 |
| Chopp, M; Kassis, H; Liu, X; Tang, T; Teng, H; Zhang, L; Zhang, ZG | 1 |
| Chopp, M; Hozeska, A; Liu, X; Lu, M; Riordan, W; Stagliano, N; Zhang, L; Zhang, ZG | 1 |
| Kamada, N; Kikuchi, S; Kobayashi, S; Komatsu, Y; Kusama, H; Mukaiyama, H; Nishimura, T; Oonota, H; Ozawa, T | 1 |
| Liao, F | 1 |
2 review(s) available for pyrazines and Stroke
| Article | Year |
|---|---|
The neurovascular unit and combination treatment strategies for stroke.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cerebral Hemorrhage; Drug Therapy, Combination; Erythropoietin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Minocycline; Pyrazines; Stroke; Tissue Plasminogen Activator | 2012 |
Herbs of activating blood circulation to remove blood stasis.
Topics: Aged; Animals; Anticoagulants; Blood Viscosity; Cardiovascular Agents; Coronary Disease; Drugs, Chinese Herbal; Fibrinolytic Agents; Hemodynamics; Hemorheology; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazines; Rats; Rats, Wistar; Stroke; Thrombosis | 2000 |
2 trial(s) available for pyrazines and Stroke
| Article | Year |
|---|---|
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Pyrazines; Research Design; Sitagliptin Phosphate; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles | 2013 |
Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; International Cooperation; Male; Middle Aged; Neuroprotective Agents; Phosphodiesterase 5 Inhibitors; Pyrazines; Pyridines; Severity of Illness Index; Stroke; Time Factors | 2016 |
18 other study(ies) available for pyrazines and Stroke
| Article | Year |
|---|---|
A combination of tetramethylpyrazine hydrochloride and butylphthalide on serum S100B, CRP, Hcy levels and NIHSS score in patients with acute cerebral infarction: A retrospective study.
Topics: Acute Disease; Benzofurans; Brain Ischemia; Cerebral Infarction; Humans; Pyrazines; Retrospective Studies; S100 Calcium Binding Protein beta Subunit; Stroke | 2022 |
Hybrid molecules of scutellarein and tertramethylpyrazine's active metabolites for ischemic stroke.
Topics: Animals; Apigenin; Brain Ischemia; Disease Models, Animal; Infarction, Middle Cerebral Artery; Neurons; Neuroprotective Agents; PC12 Cells; Pyrazines; Rats; Reperfusion Injury; Stroke | 2019 |
Dose-dependent effects of tetramethylpyrazine on the characteristics of human umbilical cord mesenchymal stem cells for stroke therapy.
Topics: Cell Movement; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pyrazines; Stroke; Umbilical Cord; Vasodilator Agents | 2020 |
Sustained Neurological Recovery After Stroke in Aged Rats Treated With a Novel Prostacyclin Analog.
Topics: Acetates; Age Factors; Animals; Brain Ischemia; Epoprostenol; Infarction, Middle Cerebral Artery; Male; Pyrazines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Prostaglandin; Stroke | 2017 |
Therapeutic Potential of Novel Twin Compounds Containing Tetramethylpyrazine and Carnitine Substructures in Experimental Ischemic Stroke.
Topics: Animals; Brain Ischemia; Carnitine; Disease Models, Animal; Male; NADPH Oxidase 2; Neuroprotective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; Stroke | 2017 |
Novel neuroprotective tetramethylpyrazine analog T-006 promotes neurogenesis and neurological restoration in a rat model of stroke.
Topics: Animals; Disease Models, Animal; Doublecortin Protein; Hydrazones; Male; Nerve Regeneration; Neurogenesis; Neuroprotective Agents; Pyrazines; Rats; Rats, Sprague-Dawley; Recovery of Function; Stroke | 2019 |
All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
Topics: Denmark; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrazines; Retrospective Studies; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles | 2014 |
Simple benchmark for complex dose finding studies.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Benchmarking; Biometry; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Lymphoma; Models, Statistical; Pyrazines; Stroke; Urinary Bladder Neoplasms | 2014 |
Sitagliptin After Ischemic Stroke in Type 2 Diabetic Patients: A Nationwide Cohort Study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Stroke; Treatment Outcome; Triazoles | 2015 |
A Novel Ligustrazine Derivative T-VA Prevents Neurotoxicity in Differentiated PC12 Cells and Protects the Brain against Ischemia Injury in MCAO Rats.
Topics: Animals; Behavior, Animal; Brain Ischemia; Ca(2+) Mg(2+)-ATPase; Cell Differentiation; Cell Survival; Cyclooxygenase 2; Disease Models, Animal; Immunohistochemistry; Neuroprotective Agents; NF-kappa B; PC12 Cells; Pyrazines; Rats; Stroke; Superoxide Dismutase; Toxicity Tests, Acute; Vascular Endothelial Growth Factor A | 2015 |
Tetramethylpyrazine nitrone, a multifunctional neuroprotective agent for ischemic stroke therapy.
Topics: Animals; Biomarkers; Blood-Brain Barrier; Brain Infarction; Disease Models, Animal; Macaca fascicularis; Male; Nerve Tissue Proteins; Neuroprotective Agents; Pyrazines; Schiff Bases; Stroke | 2016 |
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
Topics: Animals; Antioxidants; Brain Ischemia; Fibrinolytic Agents; Nitrogen Oxides; Pyrazines; Rats; Stroke; Thrombolytic Therapy | 2008 |
Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; China; Dexamethasone; Humans; Male; Multiple Myeloma; Pyrazines; Recurrence; Stroke; Thrombosis; Treatment Outcome | 2010 |
Pharmacokinetic study of a novel stroke therapeutic, 2-[[(1,1-dimethylethyl)oxidoimino]methyl]-3,5,6-trimethylpyrazine, by a simple HPLC-UV method in rats.
Topics: Animals; Calibration; Chromatography, High Pressure Liquid; Half-Life; Indicators and Reagents; Pyrazines; Quality Control; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet; Stroke | 2011 |
Neuroprotective effects of NKN on focal cerebral ischemia in rats.
Topics: Abietanes; Acetophenones; Animals; Benzoates; Brain Ischemia; Bridged-Ring Compounds; Drug Combinations; Endothelin-1; Glucosides; Immunohistochemistry; In Situ Hybridization; Infarction, Middle Cerebral Artery; Male; Malondialdehyde; Neurologic Examination; Neurons; Neuroprotective Agents; Pyrazines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Stroke; Superoxide Dismutase | 2012 |
Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway.
Topics: Aging; Animals; Boronic Acids; Bortezomib; Cells, Cultured; Down-Regulation; Drug Therapy, Combination; Humans; Male; MicroRNAs; Neuroprotective Agents; NF-kappa B; Pyrazines; Rats; Rats, Wistar; Signal Transduction; Stroke; Tissue Plasminogen Activator; Toll-Like Receptors | 2012 |
Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
Topics: Animals; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Brain; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; Intracranial Embolism; Male; NF-kappa B; Nitric Oxide Synthase Type III; Platelet Aggregation; Protease Inhibitors; Pyrazines; Rats; Rats, Wistar; Recombinant Proteins; Stroke; Time Factors; Tissue Plasminogen Activator; Vascular Patency | 2006 |
Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke.
Topics: Acute Disease; Animals; Brain Ischemia; Crystallography, X-Ray; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Indicators and Reagents; Magnetic Resonance Spectroscopy; Mass Spectrometry; Models, Molecular; Molecular Conformation; Neuroprotective Agents; Pyrazines; Rats; Spectrophotometry, Infrared; src-Family Kinases; Stroke; Structure-Activity Relationship | 2007 |